These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 1313549

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 3. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Macdonald PS, Keogh AM, Marshman D, Richens D, Harvison A, Kaan AM, Spratt PM.
    J Heart Lung Transplant; 1995 Jan 27; 14(1 Pt 1):32-8. PubMed ID: 7727473
    [Abstract] [Full Text] [Related]

  • 4. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ, Busuttil RW.
    Transplantation; 2004 Jan 27; 77(2):305-8. PubMed ID: 14742998
    [Abstract] [Full Text] [Related]

  • 5. [Value of a short (7 days) prophylactic course of ganciclovir in the prevention of cytomegalovirus disease after heart transplantation].
    Giménez D, María Arizón J, de la Torre J, Anguita M, Escauriaza J, López Granados A, Mesa D, Torres F, Casares J, Concha M, Vallés F.
    Rev Esp Cardiol; 1996 Jan 27; 49(1):35-40. PubMed ID: 8685510
    [Abstract] [Full Text] [Related]

  • 6. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 27; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A.
    J Heart Lung Transplant; 1995 Sep 27; 14(4):659-65. PubMed ID: 7578172
    [Abstract] [Full Text] [Related]

  • 9. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC.
    N Engl J Med; 1999 May 13; 340(19):1462-70. PubMed ID: 10320384
    [Abstract] [Full Text] [Related]

  • 10. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.
    Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA.
    N Engl J Med; 1991 Apr 11; 324(15):1005-11. PubMed ID: 1848679
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
    Sakai R, Maruta A, Taguchi J, Tomita N, Fujita H, Kodama F, Ogawa K, Fujisawa S, Matsuzaki M, Motomura S, Okubo T.
    Rinsho Ketsueki; 1996 Jan 11; 37(1):14-21. PubMed ID: 8683862
    [Abstract] [Full Text] [Related]

  • 13. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
    Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD.
    N Engl J Med; 1991 Dec 05; 325(23):1601-7. PubMed ID: 1658652
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
    Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M.
    Bone Marrow Transplant; 1994 Apr 05; 13(4):461-4. PubMed ID: 8019472
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Incidence, prevention and therapy of cytomegalovirus and pneumocystis carinii infection after heart transplantation].
    Vetter H, Reichenspurner H, Uberfuhr P, Netz H, Reichart B.
    Med Klin (Munich); 1992 Oct 05; 87 Suppl 1():56-9. PubMed ID: 1334222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.